Investigation of survivin gene polymorphism in patients with gastric carcinoma

Yıl 2012, Cilt: 39 Sayı: 4, 499 - 503, 01.12.2012

Nesibe Yamak Kürşat Oğuz Yaykaşlı Hatice Soğuktaş Murat Oktay Havva Erdem Ertuğrul Kaya Aysun Ekinci Savaş Kaya Yener Kurman

https://doi.org/10.5798/diclemedj.0921.2012.04.0189

Cited By: 1

Öz

Objectives: Despite decreasing incidence of gastric cancer in worldwide, it is still a major health problem. Every year, 30.000 new gastric cancer cases emerging, and it is the second most common cancer in Turkey. Gastric cancer is a complex multifactorial disease, emerging by interaction between genetic and environmental factors. Survivin, apoptosis inhibitory protein is over-expressed in cancer tissue. In this study, association between Survivin -31G/C polymorphism and gastric carcinoma was investigated. Materials and Methods: 46 gastric carcinoma patients who had been admitted at Düzce University Research and Practice Hospital, Laboratory of Pathology and 42 healthy individuals have been included in the study. Samples have been subjected to genetic analysis by PCR-RFLP method in Medical Genetics Department laboratory at Düzce University. Results: GG genotype was found in 16 (34.8%), GC genotype in 21 (45.7%), CC genotype in 9 (19.6%) in patient group. In control group, genotype distribution were found 13 (31%), 26 (61.9%) and 3 (7.1%) respectively. The statistically significant difference was not found when compared between patient and control groups. However, we observed the increased occurrence of gastric cancer associated with CC genotype (OR=1.52). Conclusions: In our knowledge, this study is the first to evaluate the relationship between gastric carcinoma and Survivin -31G/C polymorphism in Turkish population. Our results show that there is no any association between gastric carcinoma and Survivin -31G/C polymorphism in the community which is represented by our study and control groups. However, it was concluded that CC genotype may create the susceptibility to gastric cancer.

Anahtar Kelimeler

Polymorphism, gastric carcinoma, surviving gene, apoptosis

Mide kanseri hastalarında survivin gen polimorfizmi araştırılması

Öz

Amaç: Dünya genelinde mide kanserinin insidansı düşmesine rağmen hala önemli bir sağlık problemidir. Türkiye\'de ise yılda 30.000 yeni mide kanseri vakasıyla 2. en sık görülen kanserdir. Mide kanseri genetik ve çevresel faktörlerin etkileşimiyle ortaya çıkan çok faktörlü karmaşık bir hastalıktır. Kanserli dokuda aşırı ifade edilen survivin, apoptozis inhibe edici proteinlerdendir. Bu çalışmada Survivin -31 G/C polimorfizmi ile mide kanseri arasındaki ilişki araştırıldı. Gereç ve yöntem: Çalışma Düzce Üniversitesi Araştırma ve Uygulama Hastanesi Patoloji Laboratuvarına gelen mide kanseri tanısı konmuş 46 hasta ve sağlıklı bireylerin oluşturduğu 42 kişilik kontrol grubu ile gerçekleştirildi. Bu bireylerin genotipi Düzce Üniversitesi, Tıp Fakültesi, Tıbbi Genetik Anabilim Dalı Laboratuvarlarında PCR-RFLP yöntemiyle tayin edildi. Bulgular: Hasta grubunda, GG genotipi 16 (% 34,8), GC genotipi 21 (% 45,7) ve CC genotipi ise 9 (% 19,6) olguda saptandı. Kontrol grubunda ise, genotip dağılımı sırasıyla 13 (% 31), 26 (% 61,9) ve 3 (% 7,1) bulundu. Hasta ve kontrol grubu karşılaştırıldığında istatistiksel olarak anlamlı bir fark saptanamadı. Fakat CC genotipine sahip bireylerin mide kanserine yakalanma riskinin GG (OR=1,52) daha fazla risk oluşturduğu bulundu. Sonuç: Bu çalışma bildiğimiz kadarıyla Türk toplumunda mide kanseri ile Survivin -31G/C polimorfizmini araştıran ilk çalışmadır. Elde ettiğimiz sonuçlar hasta ve kontrol gruplarımızın temsil ettiği toplum kesitinde mide kanseri ile Survivin -31 G/C polimorfizmi arasında anlamlı bir ilişki olmadığını göstermekle birlikte CC genotipinin mide kanserine yatkınlık oluşturduğu düşünülebilir.

Anahtar Kelimeler

Polimorfizm, mide kanseri, survivin gen, apoptozis

Kaynakça

• Kelle İ, Kanser Tedavisinde Biyotoksinler. Dicle Tıp Dergisi 2007;34(3):226-32.
• Bertuccio P, Chatenoud L, Levi F, et al. Recent pat- terns in gastric cancer: a global overview. Int J Cancer 2009;125(5):666-73.
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D Global cancer statistics. CA Cancer J Clin 2011; 61(1):69- 90.
• Tuncer AM. Türkiye’de Kanser Kontrolü. Ankara: Onur Matbaacılık, 2007.
• Liu KJ, Qi HZ, Yao HL, et al. An updated meta-analysis of the p53 codon 72 polymorphism and gastric cancer risk, Mol Biol Rep 2012; 39(124):8265-75.
• Ekmekçi A, Konaç E, Önen Hİ. Gene polimorphism and genetic susceptibility to cancer. Marmara Med J 2008; 21(3):282-95.
• Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma, Nat Med 1997; 3(8):917-21.
• Deveraux QL, Reed JC. IAP family proteins--suppressors of apoptosis, Genes Dev 1999; 13(3):239-52.
• Jang JS, Kim KM, Kang KH, et al. Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer. 2008; 60(1):31-9.
• Andric M, Nikolic N, Boskovic M, et al. Survivin gene pro- moter polymorphism -31G/C as a risk factor for keratocys- tic odontogenic tumor development, Eur J Oral Sci 2012; 120(1):9-13.
• Yazdani N, Sayahpour FA, Haghpanah V, et al. Survivin gene polymorphism association with papillary thyroid car- cinoma, Pathol Res Pract.2012; 15:208(2):100-3.
• Wang YH, Chiou HY, Lin CT, et al. Association between survivin gene promoter -31 C/G polymorphism and urothe- lial carcinoma risk in Taiwanese population. Urology 2009; 73(5):670-4.
• Gazouli M, Tzanakis N, Rallis G, et al. Survivin -31G/C promoter polymorphism and sporadic colorectal cancer. Int J Colorectal Dis 2009; 24(1):145-50.
• Jaiswal PK, Goel A, Mandhani A, Mittal RD. Functional polymorphisms in promoter survivin gene and its associa- tion with susceptibility to bladder cancer in North Indian cohort. Mol Biol Rep 2012; 39(24):5615-21.
• Borbely AA, Murvai M, Szarka K, et al. Survivin promoter polimorphism and cervical carcinogenesis. J Clin Pathol 2007; 60(2):303-306.
• Han CH, Wei Q, Lu KK, Liu Z, Mills GB, Wang L. Poly- morphisms in the survivin promoter are associated with age of onset of ovarian cancer. Int J Exp Med 2009; 2(2):289- 299.
• Altieri DC. The molecular basis and potential role of sur- vivin in cancer diagnosis and therapy, Trends Mol Med 2001; 7(4):542-7.
• Ma F, Zhang H, Zhai Y, et al. Functional polymorphism -31C/G in the promoter of BIRC5 gene and risk of naso- pharyngeal carcinoma among chinese, PLoS One 2011; 3:6:e16748.
• Qin C, Cao Q, Li P, et al. Functional promoter -31G>C vari- ant in survivin gene is associated with risk and progression of renal cell cancer in a Chinese population, PLoS One 2012;7:e28829.